Clostridium difficile (C. difficile): bacteria, disease, and public health

Biology and key characteristics

C. difficile is notable for several microbiological features that influence how it spreads and causes disease. It is Gram-positive in staining characteristics (Gram stain details), anaerobic, and capable of forming highly resistant spores that survive for long periods outside the body. In the intestine, it may exist as part of the flora or overgrow when normal microbiota are disrupted.

• Spore formation: permits persistence on surfaces and resistance to disinfectants.
• Toxin production: many disease manifestations are mediated by toxins that damage intestinal cells.
• Colonization: it can live in the human colon without causing symptoms in a proportion of adults.

Clinical disease: presentation and complications

When C. difficile multiplies unchecked, it damages the lining of the large intestine and can produce a condition known as colitis. This term describes inflammation of the colon (inflammation), which can range from mild diarrhea to severe, life-threatening inflammation with systemic illness. The clinical syndrome is usually referred to as C. difficile infection (CDI) and may present with frequent watery stools, abdominal pain, fever, and elevated white blood cell counts. Severe cases can lead to toxic megacolon, perforation, or sepsis.

History, epidemiology and public health impact

CDI has become increasingly recognized since the late 20th century, particularly in hospitals, long-term care facilities, and other health-care environments where antibiotic exposure is common and vulnerable patients are concentrated. Outbreaks in institutional settings have highlighted the organism's ability to spread via spores on surfaces and hands. C. difficile infection rates rose in many countries during the 2000s and attracted attention because of increased severity in some strains. It is associated with substantial morbidity and mortality; estimates published by national health authorities have cited thousands of deaths annually in the United States (national data) and remains an important target of infection-prevention programs in health-care facilities.

Prevention, diagnosis and treatment

Preventive measures focus on antibiotic stewardship, hand hygiene, and environmental cleaning to remove spores. Diagnosis typically combines clinical assessment with laboratory testing for C. difficile toxins or toxin genes. Treatment strategies vary by severity: mild to moderate cases are commonly treated with specific antibiotics directed at C. difficile, while severe or recurrent infections may require alternative agents, prolonged therapy, fecal microbiota transplantation, or surgical intervention in life-threatening situations.

• Prevention: prudent antibiotic use, handwashing, and environmental disinfection.
• Diagnosis: stool testing for toxin or PCR assays.
• Treatment options: targeted antibiotics, supportive care, and for recurrent disease, microbiome-based therapies.

Notable distinctions and ongoing issues

Important considerations include the role of asymptomatic carriage (a proportion of healthy adults carry C. difficile in the colon), the persistence of spores on surfaces, and the risk that common antibiotics pose by disrupting normal gut flora. Research continues into vaccines, improved diagnostics, and strategies to prevent recurrence. For clinical guidance and surveillance data see sources from public health agencies and infectious disease specialists (overview, laboratory guidance, clinical information, inflammation, colitis resources, taxonomy, national statistics, facility guidance, genus information, colon carriage studies).